Delivery Order SPE2DB24D9224-SPE2DB25FJGFQ
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on July 22, 2025, for 60 tablets of Xtandi 80 mg, a prescription medication commonly used in oncology treatment. The delivery order, valued at $4,169.59 with firm fixed pricing, is expected to be completed by July 23, 2025. This award carries no set-aside designation and represents a direct distribution of...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 on August 12, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The Defense Logistics Agency issued this firm fixed-price delivery order under its larger Indefinite Delivery Contract with DMS Pharmaceutical Group, which is valued at $500 million and remains active through November 2026. The contract carries no set-aside...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,311.35 by the Defense Logistics Agency (DLA) on July 31, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order carries an ultimate completion date of August 1, 2025, and was issued without set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,017.54 on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award was issued under a firm fixed-price contract type with no set-aside designation, reflecting the company's competitive standing in federal procurement markets. The funding agency is the Defense Logistics Agency's Medical Supply Chain division, and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The place of performance is located in Park Ridge, Illinois, where the vendor...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $4,311.35 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on July 18, 2025, for 120 capsules of Xtandi 40 mg. The delivery order is not designated as a set-aside contract and carries an ultimate completion date of July 21, 2025. This award represents a single delivery transaction executed under DMS Pharmaceutical Group's larger Indefinite...
- SPE2DB24D9224Indefinite Delivery Contract
- SPE2DB24D9224-SPE2DB25FJGFQDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a firm fixed-price delivery order from the Defense Logistics Agency (DLA) valued at $4,169.59 for 60 tablets of Xtandi 80 mg. The award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a standard pharmaceutical supply delivery to support Department of Defense healthcare operations. This delivery order was issued without a set-aside designation, demonstrating the company's competitive positioning in federal pharmaceutical procurement markets. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which is valued at $499,999,999 and remains valid through November 2026. The IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting military health facilities worldwide. Xtandi, an oncology medication, is consistent with the contractor's established portfolio of specialty pharmaceutical products delivered to federal healthcare systems, which includes branded and generic prescription drugs, biologics, and medical consumables across multiple therapeutic categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 8/15/25 |